--------------------------- INDICATIONS AND USAGE ----------------------------
JULUCA, a two-drug combination of dolutegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, a HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. (1)
----------------------- DOSAGE AND ADMINISTRATION -----------------------
⋅One tablet taken orally once daily with a meal. (2.1)
⋅Rifabutin coadministration: Take an additional 25-mg tablet of rilpivirine with JULUCA once daily
